Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

发表于 5 天前

期刊：BMJ

文献作者：Miao-Zhen Qiu; Do-Youn Oh; Ken Kato; Tobias Arkenau; Josep Tabernero; Marcia Cruz Correa; Anastasia V Zimina; Yuxian Bai; Jianhua Shi; Keun-Wook Lee; Jufeng Wang; Elena Poddubskaya; Hongming Pan; Sun Young Rha; Ruixing Zhang; Hidekazu Hirano; David Spigel; Kensei Yamaguchi; Yee Chao; Lucjan Wyrwicz; Umut Disel; Roberto Pazo Cid; Lorenzo Fornaro; Ludovic Evesque; Hongwei Wang; Yaling Xu; Jiang Li; Tao Sheng; Silu Yang; Liyun Li; Markus Moehler; Rui-Hua Xu

出版日期：--

DOI号：10.1136/bmj-2023-078876

下载链接：http://data.bmj.org/tdm/10.1136/bmj-2023-078876

文献链接：https://doi.org/10.1136/bmj-2023-078876

当前文献来源于 BMJ。

备注信息：

发表于 5 天前

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[BMJ] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[BMJ] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial 一键复制